ICH M7 & Nitrosamines Impurities -Updates

Of course, the details of ongoing ICH discussions cannot be shared publicly until they are authorized for disclosure.

One thing that caught my attention was @SSimon’s comment during the Q&A session at the Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop. She mentioned that the Error-Corrected Sequencing (ECS) spectra for NDEA and N-nitroso-bisoprolol were quite different.

Recent discussions on read-across have also highlighted that surrogate selection should consider not only structural similarity but also physicochemical properties, pharmacokinetics (PK), and structural features or mechanisms relevant to toxicity.

I hope that, as these aspects become better understood and systematically evaluated, a framework for establishing acceptable intake limits for NDSRIs that are negative in in vivo mutagenicity studies will also emerge.

Let’s keep an eye on how this discussion develops.

2 Likes

This response to: "When a mutagenic impurity cannot be controlled to the TTC, results from an appropriate ‘in vivo’ assay could complement the available data for a weight-of-evidence approach to support a higher limit on a case-by-case basis. However, in vivo gene mutation assays alone are currently not validated to directly assess cancer risk because the endpoint is mutation and not carcinogenicity. —

I can share that we are making good progress in the working group.

5 Likes